ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma

Neuro-Oncology

Volumn 12, Issue 8, 2010, Pages 834-843

  Ammoun, Sylwia ^a   Cunliffe, Clare H ^b   Allen, Jeffrey C ^b   Chiriboga, Luis ^b   Giancotti, Filippo G ^c   Zagzag, David ^b   Hanemann, C Oliver ^a,d   Karajannis, Matthias A ^b  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

EGFR; ErbB2; Receptor tyrosine kinases; Targeted therapy; Vestibular schwannoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; LAPATINIB; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PROTEIN TYROSINE KINASE; SURVIVIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEURILEMOMA; NEUROFIBROMATOSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; VESTIBULAR SCHWANNOMA; CELL SURVIVAL; DRUG EFFECT; METABOLISM; NEUROMA; PHYSIOLOGY; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROMA, ACOUSTIC; PROTEIN ARRAY ANALYSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 78149474027     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq012     Document Type: Article

References (49)

1. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.
2. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature. 1993;363:515-521.
3. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;75:826.
4. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004;23:1739-1748.
5. Takahashi K, Suzuki K. Density-dependent inhibition of growth involves prevention of Egf receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res. 1996;226:214-222.
6. Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO. Impaired intercellular adhesion and immature adherens junctions in Merlindeficient human primary Schwannoma cells. Glia. 2008;56:506-515.
7. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors Merlin and expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol. 2006;16:702-709.
8. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1/Jnk signaling pathway in primary human Schwannoma cells. Hum Mol Genet. 2003;12:1211-1221.
9. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007;67: 520-527.
10. Fraenzer JT, Pan H, Minimo L, Jr, Smith GM, Knauer D, Hung G. Overexpression of the Nf2 gene inhibits Schwannoma cell proliferation through promoting Pdgfr degradation. Int J Oncol. 2003;23: 1493-1500.
11. Lim JY, Kim H, Kim YH, et al. Merlin suppresses the Sre-dependent transcription by inhibiting the activation of Ras-Erk pathway. Biochem Biophys Res Commun. 2003;302:238-245.
12. Hanemann CO. Magic but treatable? Tumours due to loss of Merlin. Brain. 2008;131:606-615.
13. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human Schwannoma. Cancer Res. 2008;68:5236-5245.
14. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of Egfr signaling by Nf2/Merlin. J Cell Biol. 2007;177:893-903.
15. Stonecypher MS, Chaudhury AR, Byer SJ, Carroll SL. Neuregulin growth factors and their Erbb receptors form a potential signaling network for schwannomatumorigenesis. JNeuropathol ExpNeurol. 2006;65:162-175.
16. Hansen MR, Roehm PC, Chatterjee P, Green SH. Constitutive neuregulin-1/Erbb signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53:593-600.
17. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR. The Erbb inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol. 2008;29:846-853.
18. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172-187.
19. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of Nf2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008;5:487-491.
20. Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/Akt signaling pathway in breast cancer cells. Cancer Res. 2005;65:11018-11025.
21. Xia W, Bisi J, Strum J, et al. Regulation of survivin by Erbb2 signaling: therapeutic implications for Erbb2-overexpressing breast cancers. Cancer Res. 2006;66:1640-1647.
22. Wang Q, Greene MI. Egfr enhances survivin expression through the phosphoinositide 3 (Pi-3) kinase signaling pathway. Exp Mol Pathol. 2005;79:100-107.
23. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and Pten with survival in childhood gliomas. Clin Cancer Res. 2008;14:3386-3394.
24. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis Type 2 patients. Neurobiol Dis. 1998;5:55-64. (Pubitemid 28361652)
25. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO. Reduced apoptosis rates in human schwannomas. Brain Pathol. 2005;15:17-22.
26. Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S, Utermark T. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol. 2006;32:605-614.
27. Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28:854-865.
28. Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006;17:295-304.
29. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. Ron, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 2005;12:273-281.
30. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the Ron receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 2007;213:402-411.
31. Wang J, Rajput A, Kan JL, et al. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem. 2009;284:10912-10922.
32. Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI. The soluble sema domain of the Ron receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem. 2004;279:3726-3732.
33. Hilton DA, Ristic N, Hanemann CO. Activation of Erk, Akt and Jnk signalling pathways in human schwannomas in situ. Histopathology 2009;55:744-749.
34. James MF, Han S, Polizzano C, et al. Nf2/Merlin is a novel negative regulator of Mtor complex 1, and activation of Mtorc1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29: 4250-4261.
35. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor Gene Nf2, encoding Merlin, constitutively activates integrin-dependent Mtorc1 signaling. Mol Cell Biol. 2009;29: 4235-4249.
36. Doherty JK, OngkekoW, Crawley B, Andalibi A, Ryan AF. Erbb and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol. 2008;29:50-57.
37. Birchmeier C, Nave KA. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia. 2008;56: 1491-1497.
38. Hansen MR, Linthicum FH Jr. Expression of neuregulin and activation of Erbb receptors in vestibular schwannomas: possible autocrine loop stimulation. Otol Neurotol. 2004;25:155-159.
39. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of Egfr and Her2 tyrosine kinase activity. Expert Opin Biol Ther. 2007;7:257-268.
40. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of Gw572016, a dual tyrosine kinase inhibitor blocks Egf activation of Egfr/Erbb2 and downstream Erk1/2 and Akt pathways. Oncogene. 2002;21: 6255-6263.
41. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual Erbb-2/Egfr, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61:7196-7203.
42. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/Erbb-2 tyrosine kinase inhibitor, Gw2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85-94.
43. Spector NL, Xia W, Burris H 3rd, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of Erbb1 and Erbb2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23:2502-2512.
44. Hassounah M, Lach B, Allam A, et al. Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosis. J Neurooncol. 2005;72: 203-208.
45. Katoh M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G, Dietrich PY. Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol. 2003;64:71-76.
46. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
47. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100:1092-1103.
48. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2- positive breast cancer. J Clin Oncol. 2008;26:1993-1999.
49. Dhillon S, Wagstaff AJ. Lapatinib. Drugs. 2007;67:2101-2108; discussion 2109-2110.